ABSTRACT
Background Smoking rates are significantly higher in people with mental health problems, compared to those without. Negative attitudes towards smoking cessation are widespread in inpatient settings towards patients with severe and enduring mental illness. It is not clear if the same attitudes operate in psychological services towards people with common mental illness. We aimed to understand the concerns and views that patients, therapists, and smoking cessation practitioners may have about integrating smoking cessation treatment into psychological treatment for common mental illness and how these concerns may be overcome.
Methods Thematic analysis of 23 in-depth interviews. Interviews took place in Improving Access to Psychological Therapies (IAPT) and smoking cessation services in England. Participants were 11 psychological wellbeing practitioners (PWPs), six IAPT patients with common mental illness, and six smoking cessation advisors.
Outcomes None.
Findings IAPT patients reported psychological benefits from smoking, but also described smoking as a form of therapeutic self-harm. PWPs seem positive towards smoking cessation treatment for people with common mental illness. IAPT PWPs and patients accept evidence that smoking tobacco may harm mental health, and quitting might benefit mental health. PWPs report expertise in helping people with common mental illness to make behavioural changes in the face of mood disturbances and poor motivation. IAPT appears to be a natural environment for smoking cessation intervention. PWPs felt confident to offer smoking cessation treatments to IAPT patients, but thought that a reduction in caseload was required to deliver smoking cessation support in an already pressed service.
Competing Interest Statement
Alison Heawood (nee Shaw) and David Kessler have no conflicts of interest. Gemma Taylor and Marcus Munafò have previously received funding from Pfizer, who manufacture smoking cessation products, for research unrelated to this study.
Clinical Protocols
Funding Statement
Gemma Taylor and Katherine Sawyer are funded by Cancer Research UK (Population Researcher Postdoctoral Fellowship award (C56067/A21330). Alison Heawood (nee Shaw) is funded through various NIHR grants. The MRC Integrative Epidemiology Unit at the University of Bristol is supported by the Medical Research Council and the University of Bristol (MC_UU_00011/7). David Kessler is funded by The Centre for Primary Care at the University of Bristol. Paul Aveyard is funded by NIHR, CRUK, Wellcome Trust, BMA Foundation, and MRC. Paul Aveyard is an NIHR senior investigator and funded by NIHR Oxford Biomedical Research Centre and Applied Research Centre.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
FUNDING SOURCE: Gemma Taylor and Katherine Sawyer are funded by Cancer Research UK (Population Researcher Postdoctoral Fellowship award (C56067/A21330). Alison Heawood (nee Shaw) is funded through various NIHR grants. The MRC Integrative Epidemiology Unit at the University of Bristol is supported by the Medical Research Council and the University of Bristol (MC_UU_00011/7). David Kessler is funded by The Centre for Primary Care at the University of Bristol. Paul Aveyard is funded by NIHR, CRUK, Wellcome Trust, BMA Foundation, and MRC. Paul Aveyard is an NIHR senior investigator and funded by NIHR Oxford Biomedical Research Centre and Applied Research Centre.
CONFLICTS OF INTEREST: Alison Heawood (nee Shaw) and David Kessler have no conflicts of interest. Gemma Taylor and Marcus Munafò have previously received funding from Pfizer, who manufacture smoking cessation products, for research unrelated to this study.
Data Availability
Anonymised transcript data will be uploaded to the University of Bath's Research Depository, and will be restricted access data, made available only through the data guardian. These details will be released soon.
